Autosomal dominant retinitis pigmentosa (ADRP) is frequently caused by mutations in RHO, the gene for rod photoreceptor opsin. Earlier, a study on mice carrying mutated rhodopsin transgenes on either RHO + / + or RHO + /– backgrounds suggested that the amount of wild-type rhodopsin affected survival of photoreceptors. Therefore, we treated P23H RHO transgenic mice with adeno-associated virus serotype 5 (AAV5) expressing a cDNA clone of the rhodopsin gene (RHO301) that expressed normal opsin from the mouse opsin promoter. Analysis of the electroretinogram (ERG) demonstrated that increased expression of RHO301 slowed the rate of retinal degeneration in P23H mice: at 6 months, a-wave amplitudes were increased by 100% and b-wave amplitudes by 79%. In contrast, nontransgenic mice injected with AAV5 RHO301 demonstrated a decrease in the ERG, confirming the damaging effect of rhodopsin overproduction in normal photoreceptors. In P23H mice, the increase in the ERG amplitudes was correlated with improvement of retinal structure: the thickness of the outer nuclear layer in RHO301-treated eyes was increased by 80% compared with control eyes. These findings suggest that the wild-type RHO gene can be delivered to rescue retinal degeneration in mice carrying a RHO mutation and that increased production of normal rhodopsin can suppress the effect of the mutated protein. These findings make it possible to treat ADRP caused by different mutations of RHO with the expression of wild-type RHO.
Get full access to this article
View all access options for this article.
References
1.
BainbridgeJ.W.B., SmithA.J., BarkerS.S.et al.2008. Effect of gene therapy on visual function in Leber's congenital amaurosis. N. Engl. J. Med., 358:2231–2239.
2.
BokD.2007. Contributions of genetics to our understanding of inherited monogenic retinal diseases and age-related macular degeneration. Arch. Ophthalmol., 125:160–164.
3.
CashmanS.M., BinkleyE.A., Kumar-SinghR.2005. Towards mutation-independent silencing of genes involved in retinal degeneration by RNA interference. Gene Ther., 12:1223–1228.
4.
CideciyanA.V., HauswirthW.W., AlemanT.S.et al.2009. Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum. Gene Ther., 20:999–1004.
5.
DaigerS.P., BowneS.J., SullivanL.S.2007. Perspective on genes and mutations causing retinitis pigmentosa. Arch. Ophthalmol., 125:151–158.
6.
DryjaT.P., McGeeT.L., ReichelE.et al.1990. A point mutation of the rhodopsin gene in one form of retinitis pigmentosa. Nature, 343:364–366.
7.
DryjaT.P., McEvoyJ.A., McGeeT.L., BersonE.L.2000. Novel rhodopsin mutations Gly114Val and Gln184Pro in dominant retinitis pigmentosa. Invest. Ophthalmol. Vis. Sci., 41:3124–3127.
8.
FaktorovichE.G., SteinbergR.H., YasumuraD.et al.1990. Photoreceptor degeneration in inherited retinal dystrophy delayed by basic fibroblast growth-factor. Nature, 347:83–86.
9.
FarrarG.J., KennaP.F., HumphriesP.2002. On the genetics of retinitis pigmentosa and on mutation-independent approaches to therapeutic intervention. EMBO J., 21:857–864.
10.
FlanneryJ.G., ZolotukhinS., VaqueroM.I.et al.1997. Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus. Proc. Natl. Acad. Sci. U.S.A., 94:6916–6921.
FrederickJ.M., KrasnoperovaN.V., HoffmannK.et al.2001. Mutant rhodopsin transgene expression on a null background. Invest. Ophthalmol. Vis. Sci., 42:826–833.
13.
GalyA., RouxM.J., SahelJ.A.et al.2005. Rhodopsin maturation defects induce photoreceptor death by apoptosis: a fly model for RhodopsinPro23His human retinitis pigmentosa. Hum. Mol. Genet., 14:2547–2557.
14.
GorbatyukM., JustilienV., LiuJ.et al.2007a. Preservation of photoreceptor morphology and function in P23H rats using an allele independent ribozyme. Exp. Eye Res., 84:44–52.
15.
GorbatyukM., JustilienV., LiuJ.et al.2007b. Suppression of mouse rhodopsin expression in vivo by AAV mediated siRNA delivery. Vision Res., 47:1202–1208.
16.
GorbatyukM.S., PangJ., HauswirthW., LewinA.2004. Ribozyme knockdown of endogenous mouse rhodopsin by AAV-delivered ribozymes. Invest. Ophthalmol. Vis. Sci., 45:U518–U518.
17.
GorbatyukM.S., PangJ.J., ThomasJ.et al.2005a. Knockdown of wild-type mouse rhodopsin using an AAV vectored ribozyme as part of an RNA replacement approach. Mol. Vis., 11:648–656.
18.
GorbatyukM.S., TimmersA.M.M., PangJ.J.et al.2005b. Rescue of vision in P23H rats with an rAAV delivered ribozyme targeting mouse opsin. Invest. Ophthalmol. Vis. Sci., 46:4692.
19.
GorbatyukM.S., HauswirthW.W., LewinA.S.2008. Gene therapy for mouse models of ADRP. Adv. Exp. Med. Biol., 613:107–112.
20.
GorbatyukM.S., KnoxT., LavailM.M.et al.2010. Restoration of visual function in P23H rhodopsin transgenic rats by gene delivery of BiP/Grp78. Proc. Natl. Acad. Sci. U.S.A., 107:5961–5966.
IllingM.E., RajanR.S., BenceN.F., KopitoR.R.2002. A rhodopsin mutant linked to autosomal dominant retinitis pigmentosa is prone to aggregate and interacts with the ubiquitin proteasome system. J. Biol. Chem., 277:34150–34160.
23.
KiangA.S., PalfiA., AderM.et al.2005. Toward a gene therapy for dominant disease: validation of an RNA interference-based mutation-independent approach. Mol. Ther., 12:555–561.
24.
LaemmliU.K.1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227:680–685.
25.
LewinA.S., DrenserK.A., HauswirthW.W.et al.1998. Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa. Nat. Med., 4:967–971.
26.
LewisM.R., KonoM.2006. Rhodopsin deactivation is affected by mutations of Tyrl91. Photochem. Photobiol., 82:1442–1446.
27.
LinJ.H., LiH., YasumuraD.et al.2007. IRE1 signaling affects cell fate during the unfolded protein response. Science, 318:944–949.
28.
MendesH.F., van der SpuyJ., ChappleJ.P., CheethamM.E.2005. Mechanisms of cell death in rhodopsin retinitis pigmentosa: implications for therapy. Trends Mol. Med., 11:177–185.
29.
NoorwezS.M., SamaR.R.K., KaushalS.2009. Calnexin improves the folding efficiency of mutant rhodopsin in the presence of pharmacological chaperone 11-cis-retinal. J. Biol. Chem., 284:33333–33342.
30.
OlssonJ.E., GordonJ.W., PawlykB.S.et al.1992. Transgenic mice with a rhodopsin mutation (Pro23His): a mouse model of autosomal dominant retinitis-pigmentosa. Neuron, 9:815–830.
31.
O'ReillyM., Millington-WardS., PalfiA.et al.2008. A transgenic mouse model for gene therapy of rhodopsin-linked retinitis pigmentosa. Vision Res., 48:386–391.
32.
OrganisciakD.T., DarrowR.A., BarsalouL.et al.2003. Susceptibility to retinal light damage in transgenic rats with rhodopsin mutations. Invest. Ophthalmol. Vis. Sci., 44:486–492.
33.
PalfiA., AderM., KiangA.S.et al.2006. RNAi-based suppression and replacement of rds-peripherin in retinal organotypic culture. Hum. Mutat., 27:260–268.
34.
PhelanJ.K., BokD.2000. A brief review of retinitis pigmentosa and the identified retinitis pigmentosa genes. Mol. Vis., 6:116–124.
35.
RoofD.J., AdamianM., HayesA.1994. Rhodopsin accumulation at abnormal sites in retinas of mice with a human P23H rhodopsin transgene. Invest. Ophthalmol. Vis. Sci., 35:4049–4062.
36.
SaitoY., OhguroH., OhguroI.et al.2008. Misregulation of rhodopsin phosphorylation and dephosphorylation found in P23H rat retinal degeneration. Clin. Ophthalmol., 2:821–828.
37.
SimonelliF., MaguireA.M., TestaF.et al.2010. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol. Ther., 18:643–650.
StojanovicA., HwangI., KhoranaH.G., HwaJ.2003. Retinitis pigmentosa rhodopsin mutations L125R and A164V perturb critical interhelical interactions: new insights through compensatory mutations and crystal structure analysis. J. Biol. Chem., 278:39020–39028.
40.
SullivanJ.M., PietrasK.M., ShinB.J., MisasiJ.N.2002. Hammerhead ribozymes designed to cleave all human rod opsin mRNAs which cause autosomal dominant retinitis pigmentosa. Mol. Vis., 8:102–113.
41.
TamB.M., MoritzO.L.2006. Characterization of rhodopsin P23H-induced retinal degeneration in a Xenopus laevis model of retinitis pigmentosa. Invest. Ophthalmol. Vis. Sci., 47:3234–3241.
42.
TanE., WangQ., QuiambaoA.B.et al.2001. The relationship between opsin overexpression and photoreceptor degeneration. Invest. Ophthalmol. Vis. Sci., 42:589–600.
43.
TessitoreA., ParisiF., DentiM.A.et al.2006. Preferential silencing of a common dominant rhodopsin mutation does not inhibit retinal degeneration in a transgenic model. Mol. Ther., 14:692–699.
44.
TimmersA.M., ZhangH., SquitieriA., Gonzalez-PolaC.2001. Subretinal injections in rodent eyes: effects on electrophysiology and histology of rat retina. Mol. Vis., 7:131–137.
45.
Van SoestS., WesterveldA., De JongP.T.V.M.et al.1999. Retinitis pigmentosa: defined from a molecular point of view. Surv. Ophthalmol., 43:321–334.
46.
WenR., SongY., ChengT.et al.1995. Injury-induced upregulation of bFGF and CNTF mRNAs in the rat retina. J. Neurosci., 15:7377–7385.
47.
WilsonJ.H., WenselT.G.2003. The nature of dominant mutations of rhodopsin and implications for gene therapy. Mol. Neurobiol., 28:149–158.
48.
ZolotukhinS., PotterM., ZolotukhinI.et al.2002. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods, 28:158–167.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
